The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

FAD-104     7-[2-[(2R,4S)-4- [(2S,3R,4R,5S,6S)-3-fluoro...

Synonyms: AC1L3GZW, LS-74323, ME2303, ME 2303, 116521-53-0
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of ME2303

 

High impact information on ME2303

 

Chemical compound and disease context of ME2303

 

Biological context of ME2303

  • The LD50 value of ME2303 was about 140 mg/kg i.v. in mice and this value was about 7-fold higher than that of ADM [6].
  • The mean plasma concentrations of M2 were detected up to 8 and 4 h after i.v. administration of DA-125 and ME2303, respectively, to mice and were significantly higher for DA-125 than ME2303, resulting in a considerably greater AUC of M2 (148 against 27.1 micrograms min mL(-1)) after i.v. administration of DA-125 [7].
 

Anatomical context of ME2303

 

Associations of ME2303 with other chemical compounds

  • The mean plasma concentrations of M4 were detected up to 8 h after i.v. administration of both DA-125 and ME2303 to mice, and were higher after i.v. administration of DA-125 than ME2303, resulting in a considerably greater AUC of M4 (197 against 61.9 micrograms min mL(-1)) after i.v. administration of DA-125 [7].
 

Gene context of ME2303

  • These results suggest that OP, ME2303 and CPT-11 could be active in patients with, NSCLC clinically resistant to CDDP [10].
 

Analytical, diagnostic and therapeutic context of ME2303

References

  1. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Tsuruo, T., Yusa, K., Sudo, Y., Takamori, R., Sugimoto, Y. Cancer Res. (1989) [Pubmed]
  2. Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysis. Huxham, I.M., Barlow, A.L., Lewis, A.D., Plumb, J., Mairs, R.J., Gaze, M.N., Workman, P. Int. J. Cancer (1994) [Pubmed]
  3. Effects of antitumor agents on subcutaneous implants and hepatic metastases of colon carcinoma 26 in mice. Iigo, M., Nishikata, K., Nakajima, Y., Araki, E. Jpn. J. Cancer Res. (1992) [Pubmed]
  4. Antitumor activity of ME2303, a fluorine-containing anthracycline, against human tumors implanted in nude mice. Tsuruo, T., Sato, S., Yusa, K. Jpn. J. Cancer Res. (1989) [Pubmed]
  5. Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines. Takigawa, N., Ohnoshi, T., Ueoka, H., Kiura, K., Kimura, I. Acta Med. Okayama (1992) [Pubmed]
  6. Biological properties of ME2303 (FAD-104), a new anthracycline. Omoto, S., Kondo, S., Fukatsu, S., Takeuchi, T., Umezawa, K., Tsuchiya, T., Umezawa, S. Drugs under experimental and clinical research. (1988) [Pubmed]
  7. Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. Yoon, E.J., Lee, W.I., Shim, H.J., Lee, S.D., Kim, W.B., Yang, J., Lee, M.G. Biopharmaceutics & drug disposition. (1996) [Pubmed]
  8. Therapeutic activity and tissue distribution of ME2303, a new anthracycline containing fluorine, and its metabolites in mice bearing hepatic metastases of Lewis lung carcinoma. Iigo, M., Nishikata, K., Nakajima, Y., Hoshi, A., Kadosawa, H., Nakajima, S. Anticancer Drugs (1990) [Pubmed]
  9. Effects of fluoro-doxorubicin (ME2303) on microtubules: influence of different classes of microtubule-associated proteins. Fromes, Y., Gounon, P., Tapiero, H., Fellous, A. J. Protein Chem. (1996) [Pubmed]
  10. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Fukuda, M., Ohe, Y., Kanzawa, F., Oka, M., Hara, K., Saijo, N. Anticancer Res. (1995) [Pubmed]
 
WikiGenes - Universities